Bringing a genomic perspective to the safety of drug treatment in oncology

This article describes the clinical relevance of toxicity of therapies administered to patients with cancer, putting the patient, rather than disease, at the center of the evaluation of safety of anti-cancer therapy. Hence, the implications of adverse events are described from the patient perspective, focusing on the impact of patient safety on quality of life and efficacy of treatment. Issues revolving around other types of safety, such as financial toxicity, are also discussed. The role played by genetics in the assessment of a patient’s risk of adverse events is also discussed, both in relation to the potential of genomic research and in the context of current tools of fruition in clinical care.

• Publication year

  2017

• Venue

  F1000Research

• Publication date

  2017-03-29

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.12688/f1000research.10475.1PMID 28408974PMCID 5373416
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Genomewide Approach Validates Thiopurine Methyltransferase Activity Is a Monogenic Pharmacogenomic Trait

  2017cited by this paper
• Is Participation in Cancer Phase I Trials Really Therapeutic?

  2017cited by this paper
• Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer.

  2016cited by this paper
• Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.

  2016cited by this paper
• Patient-reported outcomes in the evaluation of toxicity of anticancer treatments

  2016cited by this paper
• Maintaining Insurance Access under Trump - A Strategy.

  2016cited by this paper
• Fulminant Myocarditis with Combination Immune Checkpoint Blockade.

  2016cited by this paper
• Circulating tumor DNA as a liquid biopsy for cancer.

  2015cited by this paper
• Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials.

  2015cited by this paper
• DPYD variants to predict 5-FU toxicity: the ultimate proof.

  2014cited by this paper
• Evidence Required to Demonstrate Clinical Utility of Pharmacogenetic Testing: The Debate Continues

  2014cited by this paper
• Clinical Implementation of Germ Line Cancer Pharmacogenetic Variants During the Next‐Generation Sequencing Era

  2014cited by this paper
• Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.

  2014cited by this paper
• The financial toxicity of cancer treatment: a pilot study assessing out-of-pocket expenses and the insured cancer patient's experience.

  2013cited by this paper
• Implications of genome-wide association studies in cancer therapeutics.

  2013cited by this paper
• A systemic review of Toxic Death in clinical oncology trials: an Achilles’ heel in safety reporting revisited

  2012cited by this paper
• Impact of chemotherapy dose intensity on cancer patient outcomes.

  2009cited by this paper
• Prognostic importance of 6-mercaptopurine dose intensity in acute lymphoblastic leukemia.

  1999cited by this paper
• The Importance of Planned Dose of Chemotherapy on Time: Do We Need to Change Our Clinical Practice?

  1998cited by this paper

• Pharmacogenomic Application in HER2-positive Breast Cancer

  2021influential citation
• Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia.

  2019cites this paper
• "No pain, No gain" still true with immunotherapy: When the finger shows the moon, look at the moon!

  2018cites this paper
• The 9th Santorini Conference: Systems Medicine, Personalised Health and Therapy. “The Odyssey from Hope to Practice”, Santorini, Greece, 30 September–3 October 2018

  2018cites this paper